Interview with Deepak Khanna, Senior Vice President and Managing Director UK,…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Address: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, United Kingdom
Tel: +44 (0) 1992 467272
Merck Sharp & Dohme Limited (MSD) is the UK subsidiary of Merck & Co., Inc., of Whitehouse Station, New Jersey, USA, a leading research-based pharmaceutical company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products to improve human health.
MSD has committed substantial investment to research and manufacturing in the UK because of the unrivalled scientific excellence and skills base available here. It has two sites in the UK: headquarters and pharmaceutical research and development laboratories in Hoddesdon, Hertfordshire; and manufacturing at Cramlington in Northumberland.
x MSD employs approximately 1,400 people in the UK
x MSD’s UK headquarters are located in Hoddesdon, Hertfordshire, where the company’s sales and marketing, medical services, market research and administration functions are situated
x Pharmaceutical research and development is also located at Hoddesdon. Recent investment has established Hoddesdon as a global centre of expertise in chemistry, to serve Merck & Co., Inc.’s organic and synthetic chemistry needs
x The pharmaceutical manufacturing and supply centre in Cramlington, Northumberland, continues to lead the industry and the Merck & Co., Inc. organisation in productivity, delivering important medicines to the Merck network
x There are additional administrative offices in both London and Stockley Park
x MSD has played a key role in the development of five of Merck & Co., Inc.’s products 16 medicines are manufactured in the UK by MSD
x The UK turnover in 2007 was £382 million
x The UK Sales Force is made up of around 500 field-based employees
MSD’s mission is to provide superior medicines which enhance patients’ quality of life. Of Merck & Co., Inc.’s most popular medicines, five have been discovered and 16 are manufactured by MSD in the UK.
MSD’s product portfolio covers a range of key therapy areas including atherosclerosis and cardiovascular disease, diabetes, infectious diseases, neuroscience and ophthalmology, respiratory, bone, arthritic conditions, and vaccines.
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
A roundup of the biggest stories from UK pharma, including the latest agreement between the British government and industry on a renewed drug pricing clawback scheme; GSK’s search for deals…
AstraZeneca has made a bold move by offering its in-house digital clinical trial expertise to clinical research organisations (CROs) and other pharmaceutical companies via the launch of healthtech business Evinova.…
Since its creation over 20 years ago, the National Institute for Health and Care Excellence (NICE), the Health Technology Assessment (HTA) body for England and Wales, has forged a solid…
Could the UK’s re-joining of Horizon Europe, the EU’s EUR 95 billion research funding programme, be the latest sign that the country is ready to win back its global scientific…
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report –…
The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National…
See our Cookie Privacy Policy Here
